Article
Oncology
Xiao Wang, Mengke Chen, Xiong Liang, Yu Bai, Judeng Zeng, Xiaoyi Xu, Hao Li, Jing Wang, Keyu Fan, Guijun Zhao
Summary: This study reveals that RNF135 is regulated by promoter hypermethylation and its decreased expression is associated with poor prognosis in hepatocellular carcinoma (HCC). Functional analysis demonstrates that RNF135 plays a crucial role in suppressing HCC cell migration and is involved in tumor immune microenvironment.
FRONTIERS IN ONCOLOGY
(2022)
Article
Cell Biology
Rongfeng Shi, Hui Zhao, Suming Zhao, Hongxin Yuan
Summary: This study comprehensively integrated the transcriptome profiling of DNA methylation regulators in hepatocellular carcinoma, identifying three distinct DNA methylation regulator-related molecular subtypes and constructing a prognostic and immunotherapeutic relevant gene signature. These findings contribute to the advancement of individualized immunotherapy for hepatocellular carcinoma.
Article
Biotechnology & Applied Microbiology
Huimin Shen, Hao Wu, Fengkai Sun, Jianni Qi, Qiang Zhu
Summary: This study identified key prognostic factors of iron metabolism-related and methylated genes for HCC, and constructed a prognostic model to predict overall survival of patients. The risk score calculated using gene expression of specific DEGs was found to be an independent variable correlated with HCC prognosis, providing a potential treatment strategy for HCC.
Article
Biotechnology & Applied Microbiology
Qian Yan, Ying Tang, Fan He, Jiao Xue, Ruisheng Zhou, Xiaoying Zhang, Huiyan Luo, Daihan Zhou, Xiongwen Wang
Summary: This study investigated alterations in DNA methylation patterns in hepatocellular carcinoma (HCC) using whole-genome bisulfite sequencing technology. The research identified a genome-wide hypomethylation pattern in HCC, with hyper-DMGs mainly involved in metabolism pathways and hypo-DMGs mainly involved in cell adhesion. By constructing a prognostic model based on aberrantly methylated genes, the study provided insights into the epigenetic mechanisms of HCC development.
Article
Oncology
Ganji Purnachandra Nagaraju, Begum Dariya, Prameswari Kasa, Sujatha Peela, Sujatha Peela Bassel F. El-Rayes
Summary: HCC is the most common primary malignancy of the liver, with a high fatality rate. Genetic and epigenetic aberrations are commonly observed in HCC, including chromatin remodeling, histone alterations, DNA methylation, and ncRNA expression. In-depth understanding of the epigenetics of HCC is critical for developing rational clinical strategies, improving overall survival, and predicting therapeutic outcomes.
SEMINARS IN CANCER BIOLOGY
(2022)
Article
Cell Biology
Lixu Zhu, Wenzhi Guo
Summary: This study identified the methylation characteristics of PD-1-negative HCC samples and proposed a prognostic model based on DMEGs. The tumor samples showed significantly lower ESTIMATE scores compared to normal samples, and 31 DMEGs were identified as able to distinguish PD-1-negative samples from normal samples. Functional enrichment analysis revealed the involvement of these genes in tumor-related and immune-related pathways, and potential therapeutic drugs were identified through DrugBank screening. The prognostic model based on three DMEGs demonstrated good predictive power for HCC prognosis and was validated in an independent cohort.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Oncology
Jinhua Jiang, Tinghua Yan, Fang Guo
Summary: The study confirmed a significant decrease in global genomic 5mC, 5hmC, and 5fC contents in SHCC, which were associated with lymph node metastasis. There was a correlation between HBV DNA level and reductions in 5mC, 5hmC, and 5fC levels. 5hmC content had a negative correlation with CK19 expression level in SHCC, with a decrease in CK19(5hmC+) cells contributing to poor prognosis.
Article
Oncology
Hye Ri Ahn, Geum Ok Baek, Moon Gyeong Yoon, Ju A. Son, Jung Hwan Yoon, Jae Youn Cheong, Hyo Jung Cho, Ho Chul Kang, Jung Woo Eun, Soon Sun Kim
Summary: The study reveals the overexpression of WASF2 in hepatocellular carcinoma (HCC) and its correlation with patient prognosis. Inactivation of WASF2 has anti-tumorigenic effects on HCC cells, suggesting that it could be a potential therapeutic target for HCC.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Review
Oncology
Ewa Wolinska, Maciej Skrzypczak
Summary: Hepatocellular carcinoma (HCC) is a life-threatening disease with unsatisfactory treatment outcomes. Epigenetic studies have revealed modified methylation patterns in HCC, dysfunction of enzymes engaged in DNA methylation process, aberrant function of non-coding RNAs, and histone modifications affecting gene expression.
Article
Genetics & Heredity
Yingyun Guo, Binglu Huang, Ruixue Li, Jiao Li, Shan Tian, Cheng Peng, Weiguo Dong
Summary: In patients with hepatocellular carcinoma (HCC), APOA-1 mRNA expression is negatively regulated by DNA methylation. Low APOA-1 expression may serve as a potential risk biomarker for predicting survival in HCC patients. Additionally, high APOA-1 transcription correlates with better overall survival, and APOA-1 hypermethylation is associated with progress-free survival in HCC sufferers.
FRONTIERS IN GENETICS
(2021)
Article
Oncology
Shijie Qin, Jieyun Xu, Yunmeng Yi, Sizhu Jiang, Ping Jin, Xinyi Xia, Fei Ma
Summary: The study identified 114 dysregulated mature miRNAs in HCC, primarily influenced by dysregulated transcription factors or DNA methylation. Several up-regulated miRNAs were shown to promote tumorigenesis by inhibiting tumor suppressor genes, while down-regulated miRNAs suppress abnormal cell proliferation by inhibiting oncogenes. The interplay between transcription factors and miRNAs plays a significant role in the occurrence and development of HCC, and the transcription factor FOXO1 may be an effective therapeutic target for improving the survival of HCC patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Cell Biology
Lixu Zhu, Wenzhi Guo
Summary: This study identified the methylation characteristics of PD-1-negative HCC samples and potential therapeutic drugs, and proposed a prognostic model based on UBD, CD5L, and CD213A2 methylation expression.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Oncology
Dongsheng He, Shengyin Liao, Lifang Cai, Weiming Huang, Xuehua Xie, Mengxing You
Summary: In this study, 44 methylation-driven genes were identified and three prognostic signatures (LCAT, RPS6KA6, and C5orf58) were screened to construct a prognostic risk model for HCC patients. Five pretreatment independent prognostic factors were identified, and a new nomogram was constructed to calculate OS with a superior C-index compared to previous studies. Additionally, correlations were found between certain methylation-driven genes and clinical parameters of HCC patients.
Article
Oncology
Huiyan Luo, Jixin Chen, Qiyin Jiang, Yifan Yu, Miaolun Yang, Yuehua Luo, Xiongwen Wang
Summary: In this study, an epigenomics analysis was conducted to identify common pathogenetic processes between SARS-CoV-2 infection and HCC patients. The co-pathogenesis was found to be closely linked to immune response, particularly T cell differentiation and monocyte differentiation. Hub genes were identified and correlated with SARS-CoV-2 infection and the prognosis of HCC patients. Mefloquine and thioridazine were identified as potential therapeutic agents for COVID-19 in combination with HCC.
CLINICAL EPIGENETICS
(2023)
Article
Cell Biology
Jiyuan Xing, Shen Shen, Zihui Dong, Xiaobo Hu, Lixia Xu, Xiaorui Liu, Qinggang Li, Yize Zhang, Gangying Cui, Zujiang Yu
Summary: The study investigated RNA modifications in HCC, identifying distinct RNA modification patterns characterized by different TME features. A scoring model, WM-Score, was developed as a reliable prognostic and immunotherapeutic effect predictor for HCC patients.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Oncology
Jingling Jin, Junliang Jin, Sarah E. Woodfield, Roma H. Patel, Nan Ge Jin, Yan Shi, Bin Liu, Wenjing Sun, Xiangmei Chen, Yang Yu, Sanjeev A. Vasudevan
Article
Oncology
Hui Li, Yang Yu, Yanling Zhao, Deanna Wu, Xiaoman Yu, Jiaxiong Lu, Zhenghu Chen, Huiyuan Zhang, Yongguang Hu, Yuanfen Zhai, Jun Su, Ayinuer Aheman, Augusto De las Casas, Jingling Jin, Xin Xu, Zhongcheng Shi, Sarah E. Woodfield, Sanjeev A. Vasudevan, Saurabh Agarwal, Yusheng Yan, Jianhua Yang, Jennifer H. Foster
Article
Oncology
Xin Xu, Wei Huang, Andras Heczey, Daofeng Liu, Linjie Guo, Michael Wood, Jingling Jin, Amy N. Courtney, Bin Liu, Erica J. Di Pierro, John Hicks, Gabriel A. Barragan, Ho Ngai, Yuhui Chen, Barbara Savoldo, Gianpietro Dotti, Leonid S. Metelitsa
CLINICAL CANCER RESEARCH
(2019)
Article
Pharmacology & Pharmacy
Shu Shi, Mingchen Liu, Jingyuan Xi, Hui Liu, Guiwen Guan, Congle Shen, Zhengyang Guo, Ting Zhang, Qiang Xu, Dilidaer Kudereti, Xiangmei Chen, Jie Wang, Fengmin Lu
ANTIVIRAL RESEARCH
(2020)
Article
Oncology
Xiaobin Zao, Jin Cheng, Congle Shen, Guiwen Guan, Xiaoyu Feng, Jun Zou, Jing Zhang, Tianxu Liu, Huiling Zheng, Ting Zhang, Jie Wang, Jia Liu, Deyao Li, Fengmin Lu, Fuping You, Xiangmei Chen
Summary: NFATc3 plays a crucial role in inhibiting hepatocarcinogenesis and HBV replication by enhancing the immune response in hepatocytes. Its downregulation in HCC is associated with poor prognosis, and its activation can promote the production of IFNs and interferon-stimulated genes to inhibit HCC cell proliferation and invasion.
Letter
Virology
Guiwen Guan, Liwei Zheng, Jingyuan Xi, Xingwen Yang, Xiangmei Chen, Fengmin Lu
Letter
Gastroenterology & Hepatology
Guiwen Guan, Jun Zou, Ting Zhang, Fengmin Lu, Xiangmei Chen
JOURNAL OF HEPATOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Chia-Chen Chen, Guiwen Guan, Xuewei Qi, Abudurexiti Abulaiti, Ting Zhang, Jia Liu, Fengmin Lu, Xiangmei Chen
Summary: This study comprehensively analyzed the characteristics of HBV integration in PLC/PRF/5 cells using third-generation sequencing technology, revealing genome instability caused by HBV integration. By selecting three combinations of sgRNAs targeting the integrated fragments, the study successfully decreased the level of HBsAg in the cells through CRISPR/Cas9 system, but may pose a potential carcinogenic risk.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2021)
Article
Oncology
Ting Zhang, Guiwen Guan, Jing Zhang, Huiling Zheng, Deyao Li, Wengong Wang, Fengmin Lu, Xiangmei Chen
Summary: The study found that AUF1 is abnormally overexpressed in hepatocellular carcinoma (HCC) and is associated with poor prognosis. Overexpression of AUF1 promotes cell proliferation and increases resistance to anticancer drugs in hepatoma cells. AKR1B10 is identified as a critical target of AUF1, and its regulation is essential for the proliferation and drug resistance of hepatoma cells. E2F1 enhances AUF1 expression at the transcription level. These findings reveal a novel role of AUF1 in the development of HCC, and the E2F1/AUF1/AKR1B10 axis may serve as a potential therapeutic target.
Article
Gastroenterology & Hepatology
Yongfeng Wang, Yongzhen Liu, Ting Zhang, Guiwen Guan, Tianhao Mao, Hui Liu, Jing Zhang, Fengmin Lu, Xiangmei Chen
Summary: This study found that CDCA3 is a potential oncogenic factor in HCC and identified a lncRNA (lncCDCA3L) that can inhibit CDCA3 expression. LncCDCA3L is significantly downregulated in HCC and its expression level is associated with tumor size and postoperative survival time in HCC patients. Mechanistically, lncCDCA3L represses CDCA3 protein level by directly binding to CDCA3 mRNA and inhibits hepatocarcinogenesis through a hairpin structure motif.
LIVER INTERNATIONAL
(2022)
Article
Biochemistry & Molecular Biology
Vivian Changying Jiang, Dapeng Hao, Preetesh Jain, Yijing Li, Qingsong Cai, Yixin Yao, Lei Nie, Yang Liu, Jingling Jin, Wei Wang, Heng-Huan Lee, Yuxuan Che, Enyu Dai, Guangchun Han, Ruiping Wang, Kunal Rai, Andrew Futreal, Christopher Flowers, Linghua Wang, Michael Wang
Summary: The study found that in patients with mantle cell lymphoma (MCL), multiple tumor-intrinsic and -extrinsic factors are associated with T-cell suppression and CAR T-cell therapy (BA) relapse, with TIGIT being a central player. The results suggest that co-targeting TIGIT may help prevent CAR T-cell relapses and promote long-term progression-free survival in MCL patients.
Article
Pathology
Jing Zhang, Ting Zhang, Guiwen Guan, Jiyun Wen, Chia-Chen Chen, Jia Liu, Yuan Duan, Yanna Liu, Xiangmei Chen
Summary: In this study, the target genes of AUF1 and its role in HCC progression were investigated. It was found that AUF1 upregulated AFP expression by enhancing the mRNA stability of AFP, thereby promoting HCC progression and doxorubicin resistance.
PATHOLOGY RESEARCH AND PRACTICE
(2023)
Editorial Material
Gastroenterology & Hepatology
Na Gao, Guiwen Guan, Qiyi Zhao, Zhiliang Gao
Summary: This article is related to Gao et al papers.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Gastroenterology & Hepatology
Na Gao, Guiwen Guan, Ganlin Xu, Haishi Wu, Chan Xie, Zhishuo Mo, Hong Deng, Shuying Xiao, Zhicong Deng, Liang Peng, Fengmin Lu, Qiyi Zhao, Zhiliang Gao
Summary: This study investigated the level and origin of HBV transcripts in patients with functional cure and their role in predicting relapse. The results showed that the levels of cccDNA and HBsAg-positive hepatocytes were significantly lower in functionally cured patients compared to uncured patients. Additionally, the levels of integrated HBV DNA and chimeric transcripts were also reduced in functionally cured patients.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Virology
Danli Yang, Jun Zou, Guiwen Guan, Xiaoyu Feng, Ting Zhang, Guixin Li, Hui Liu, Huiling Zheng, Jingyuan Xi, Guangxin Yu, Lizhong Dai, Fengmin Lu, Xiangmei Chen
Summary: This study systematically investigated the effect of A1762T/G1764A mutations on HBV replication and its underlying mechanisms. The results showed that these mutations enhance the replication ability of HBV and affect the expression levels of related RNA and proteins. In vitro and in vivo experiments confirmed that these mutations promote HBV replication and revealed their regulatory role in RNA transcription.
JOURNAL OF MEDICAL VIROLOGY
(2023)